3P Biopharmaceuticals and SpyBiotech enter into a Vaccine cGMP Manufacturing Agreement

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement withSpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases

Oxford, UK-based SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.

SpyBiotech’s proprietary SpyCatcher/SpyTag is a platform technology that allows antigens to be displayed onto virus-like particles (VLPs) with a covalent, irreversible bond in a highly stable and effective way with specific orientation/epitope presentation and high density. The technology can be used for an exceptionally broad range of applications in vaccine development and has established proof of concept data in viral, bacterial, parasitic diseases as well as chronic diseases and cancer.

cGMP Manufacturing

As 3P Biopharmaceuticals CEO Dámaso Molero explains: “It is amazing being part of a project which presents an opportunity to develop treatments for a broad range of diseases. We are helping to support cGMP manufacturing which we believe will open the door for pioneering vaccines that could offer hope for improving the lives of many people. That is extremely exciting.

Genevieve Labbe, Senior Scientist and GMP Project Manager for SpyBiotech commented: “It’s critical to have a trusted partner in place for cell line and cGMP production. SpyBiotech is looking forward to advancing this product and we are delighted to be working with 3P Biopharmaceuticals, a leading CDMO.

Through this partnership, 3P Biopharmaceuticals will once again demonstrate its capacity to carry out processes and manufacturing of molecules developed for diverse therapeutic applications, helping to consolidate its competitive position as one of the most trusted CDMOs in Europe.

Our dedicated team of specialists will be happy to discuss any of your cGMP Manufacturing needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1

Published: 15th November 2022
3P Bio will focus on the transfer of the production process as well as the cGMP manufacturing of the drug substance to be used in Phase I and II clinical trials. The novel drug could cure neurodegenerative diseases such as Amyotrophic Lateral Sclerosis.
Read more

3P Biopharmaceuticals awards the prize for the best Master’s Thesis (TFM)

Published: 3rd October 2022
At the closing of the fifth edition of the Master in Galenic Design and Manufacturing in the Pharmaceutical Industry of the University of Navarra.
Read more

3P Biopharmaceuticals among the 100 best companies to work for in Spain

Published: 27th September 2022
The prestigious ranking is based on an exhaustive questionnaire that Actualidad Económica prepares and publishes every year, and which seeks to evaluate and reward those companies whose human resources management makes them benchmarks.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.